Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Solid Tumors With MAPK Pathway Mutations”

15 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 15 results

Early research (Phase 1)Ended earlyNCT05375084
What this trial is testing

SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Who this might be right for
Non Small Cell Lung CancerSolid Tumor
Navire Pharma Inc., a BridgeBio company 21
Testing effectiveness (Phase 2)Ended earlyNCT05221320
What this trial is testing

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

Who this might be right for
Tumor, SolidGastrointestinal Cancer
BioMed Valley Discoveries, Inc 47
Early research (Phase 1)Looking for participantsNCT06299839
What this trial is testing

PAS-004 in Patients With Advanced Solid Tumors

Who this might be right for
RAS MutationNF1 MutationRAF Mutation+1 more
Pasithea Therapeutics Corp. 48
Early research (Phase 1)Ended earlyNCT05480865
What this trial is testing

SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Who this might be right for
Solid Tumor, AdultMetastatic Solid TumorMetastatic NSCLC+1 more
Navire Pharma Inc., a BridgeBio company 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT04892017
What this trial is testing

Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerAdvanced Solid TumorMetastatic Solid Tumor
Deciphera Pharmaceuticals, LLC 144
Early research (Phase 1)Ended earlyNCT06270082
What this trial is testing

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Who this might be right for
Solid Tumor, AdultColorectal CancerPancreatic Cancer+7 more
Ikena Oncology 75
Testing effectiveness (Phase 2)Active Not RecruitingNCT06287463
What this trial is testing

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Who this might be right for
Advanced Solid TumorRAF MutationRAS Mutation+7 more
Deciphera Pharmaceuticals, LLC 140
Testing effectiveness (Phase 2)Study completedNCT03213691
What this trial is testing

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+8 more
National Cancer Institute (NCI) 21
Early research (Phase 1)UnknownNCT06239623
What this trial is testing

ERK Inhibitor JSI-1187 in Advanced Solid Tumors

Who this might be right for
Solid TumorNSCLCMelanoma
JS InnoPharm, LLC 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT05578092
What this trial is testing

MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Who this might be right for
Solid TumorAdvanced Solid TumorNon Small Cell Lung Cancer+1 more
Mirati Therapeutics Inc. 228
Testing effectiveness (Phase 2)Looking for participantsNCT06310382
What this trial is testing

GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results

Who this might be right for
Advanced Solid Tumors With MAPK Signal Pathway Mutations
Suzhou Genhouse Bio Co., Ltd. 110
Early research (Phase 1)Ended earlyNCT04249843
What this trial is testing

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Who this might be right for
Solid TumorB-Raf Mutation-Related Tumors
MapKure, LLC 109
Testing effectiveness (Phase 2)Active Not RecruitingNCT03698994
What this trial is testing

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent Ependymal TumorRecurrent Ewing Sarcoma+33 more
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05886920
What this trial is testing

D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

Who this might be right for
Advanced Solid Tumors With MAPK Pathway Mutations
D3 Bio (Wuxi) Co., Ltd 67
Early research (Phase 1)Temporarily pausedNCT04418167
What this trial is testing

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Who this might be right for
Solid Tumors
JS InnoPharm, LLC 71